US FDA Wants To Help Sponsors Generate Evidence CMS Needs, But Won't Be An Intermediary

FDA-CMS communications are expected to evolve as both agencies look to improve their relationship.

collaboration
There is no completed program yet on FDA-CMS communications, FDA chief of staff Julia Tierney said. • Source: Shutterstock

The US Food and Drug Administration is interested in helping ensure sponsors collect the data needed by it and the Centers for Medicare and Medicaid Services by the time they submit marketing applications – part of an evolving effort between the agencies to improve their communications and aid sponsors.

FDA Chief of Staff Julia Tierney said 17 October that FDA staff are working hard to ensure all the necessary data – for approval and

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Market Access

HHS Negotiating With Manufacturers On Most Favored Nation Drug Pricing

 
• By 

MFN policy would would apply to all single source drugs in all insurance markets, according to HHS release. Secretary Robert F. Kennedy Jr. said the department is discussing the plan with drug sponsors.

Spain Slashes Wait Between EU Drug Authorization And Financing Decisions

 

Spanish authorities say that that timelines for drug reimbursement decisions can be improved further with the right submissions from companies.

Spain Beats England To Tevimbra Reimbursement Recommendations

 

Spanish authorities have published more pricing and reimbursement reports as part of a new drive to increase transparency.

‘Tectonic’ Arkansas PBM Legislation May Upend Industry

 
• By 

Industry will fight hard to prevent other states or the federal government from adopting measures similar to Arkansas' law preventing PBMs from owning pharmacies.

More from Pink Sheet

HHS Negotiating With Manufacturers On Most Favored Nation Drug Pricing

 
• By 

MFN policy would would apply to all single source drugs in all insurance markets, according to HHS release. Secretary Robert F. Kennedy Jr. said the department is discussing the plan with drug sponsors.

Spain Slashes Wait Between EU Drug Authorization And Financing Decisions

 

Spanish authorities say that that timelines for drug reimbursement decisions can be improved further with the right submissions from companies.

Spain Beats England To Tevimbra Reimbursement Recommendations

 

Spanish authorities have published more pricing and reimbursement reports as part of a new drive to increase transparency.